BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. Adv Ther 2021;38:1811-31. [PMID: 33650025 DOI: 10.1007/s12325-021-01654-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou L, Yan W, Li S, Yang H, Zhang X, Lu W, Liu J, Wang Y. Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies. J Glob Health 2022;12:05022. [PMID: 35712857 DOI: 10.7189/jogh.12.05022] [Reference Citation Analysis]
2 Lee S, Lee SO, Lee JE, Kim K, Lee SH, Hwang S, Kim S, Chang H, Kim Y, Bae S, Kim A, Kwon KT. Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study. International Immunopharmacology 2022;106:108570. [DOI: 10.1016/j.intimp.2022.108570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Elvidge J, Summerfield A, Nicholls D, Dawoud D. Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations. Value Health 2022:S1098-3015(22)00039-0. [PMID: 35181207 DOI: 10.1016/j.jval.2022.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ohsfeldt R, Kelton K, Klein T, Belger M, Mc Collam PL, Spiro T, Burge R, Ahuja N. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. Clin Ther 2021:S0149-2918(21)00389-1. [PMID: 34732289 DOI: 10.1016/j.clinthera.2021.09.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hadique S, Badami V, Sangani R, Forte M, Alexander T, Goswami A, Garrison A, Wen S. Coagulation Studies Are Not Predictive of Hematological Complications of COVID-19 Infection. TH Open 2022;06:e1-9. [DOI: 10.1055/s-0041-1742225] [Reference Citation Analysis]
6 Kilcoyne A, Jordan E, Thomas K, Pepper AN, Zhou A, Chappell D, Amarapala M, Thériault R, Thompson M. Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England. CEOR 2022;Volume 14:231-47. [DOI: 10.2147/ceor.s360741] [Reference Citation Analysis]
7 Kelton K, Klein T, Murphy D, Belger M, Hille E, McCollam PL, Spiro T, Burge R. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. Adv Ther 2022;39:562-82. [PMID: 34807369 DOI: 10.1007/s12325-021-01982-6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kilcoyne A, Jordan E, Zhou A, Thomas K, Pepper AN, Chappell D, Amarapala M, Hughes A, Thompson M. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective. J Med Econ 2022;:1-21. [PMID: 35037816 DOI: 10.1080/13696998.2022.2030148] [Reference Citation Analysis]
9 Rasmussen MK, Kronborg C, Fasterholdt I, Kidholm K. Economic evaluations of interventions against viral pandemics: a scoping review. Public Health 2022;208:72-9. [PMID: 35724446 DOI: 10.1016/j.puhe.2022.05.001] [Reference Citation Analysis]
10 Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs 2022;:1-18. [PMID: 35164631 DOI: 10.1080/13543784.2022.2030310] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
11 Vandepitte S, Alleman T, Nopens I, Baetens J, Coenen S, De Smedt D. Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review. Value Health 2021;24:1551-69. [PMID: 34711355 DOI: 10.1016/j.jval.2021.05.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Foglia E, Ferrario L, Schettini F, Pagani MB, Dalla Bona M, Porazzi E. COVID-19 and hospital management costs: the Italian experience. BMC Health Serv Res 2022;22:991. [PMID: 35922849 DOI: 10.1186/s12913-022-08365-9] [Reference Citation Analysis]
13 Jovanoski N, Kuznik A, Becker U, Hussein M, Briggs A. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. J Manag Care Spec Pharm 2022;28:555-65. [PMID: 35238626 DOI: 10.18553/jmcp.2022.21469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]